Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Sells $3,029,143.00 in Stock

Key Points

• Supernus Pharmaceuticals CEO Jack Khattar sold 59,900 shares for approximately $3.03 million, resulting in a 4.73% decrease in his ownership stake.
• Following the stock sale, Supernus shares traded down to $49.00, with a market capitalization of $2.75 billion and a price-to-earnings ratio of 42.61.
• Analysts have varied opinions on the stock, with price targets ranging from $46.00 to $65.00, leading to an average rating of "Buy" with a target of $64.00.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack Khattar sold 59,900 shares of the firm's stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the transaction, the chief executive officer directly owned 1,206,578 shares of the company's stock, valued at approximately $61,016,649.46. This trade represents a 4.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded down $0.51 during trading on Friday, hitting $49.00. 1,047,266 shares of the company's stock were exchanged, compared to its average volume of 654,745. The stock has a market capitalization of $2.75 billion, a price-to-earnings ratio of 42.61 and a beta of 0.78. The business has a 50-day simple moving average of $44.69 and a 200-day simple moving average of $36.56. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $51.78.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SUPN shares. Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 30th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Piper Sandler raised shares of Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $40.00 to $65.00 in a report on Thursday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $64.00.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of SUPN. Caitong International Asset Management Co. Ltd purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $41,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Supernus Pharmaceuticals during the first quarter worth about $46,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals during the third quarter worth about $50,000. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals during the second quarter worth about $51,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at approximately $55,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.